MedTrace Logo

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

NCT06568094 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-12-31

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy, and safety of HRS-5041 tablets combined with antitumor therapy in subjects with advanced prostate cancer.

Conditions

Interventions

DRUG

HRS-5041 tablets

HRS-5041 tablets

DRUG

Abiraterone Acetate tablets（II）

Abiraterone Acetate tablets（II）

DRUG

Prednisone Acetate tablets

Prednisone Acetate tablets

DRUG

Docetaxel Injection

Docetaxel Injection

DRUG

HRS-1167 tablets

HRS-1167 tablets

DRUG

SHR2554 tablets

SHR2554 tablets

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-25
Primary Completion
2026-06-30
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06568094 on ClinicalTrials.gov